Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Assets (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Assets data on record, last reported at $173.3 million in Q1 2026.

  • On a quarterly basis, Assets rose 83.85% to $173.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $173.3 million, a 83.85% increase, with the full-year FY2025 number at $181.2 million, up 83.78% from a year prior.
  • Assets reached $173.3 million in Q1 2026 per IKT's latest filing, down from $181.2 million in the prior quarter.
  • Over the last five years, Assets for IKT hit a ceiling of $181.2 million in Q4 2025 and a floor of $4.4 million in Q3 2024.
  • A 5-year average of $55.8 million and a median of $28.6 million in 2022 define the central range for Assets.
  • Peak YoY movement for Assets: plummeted 75.52% in 2024, then surged 1718.52% in 2025.
  • Tracing IKT's Assets over 5 years: stood at $24.9 million in 2022, then crashed by 41.83% to $14.5 million in 2023, then skyrocketed by 579.69% to $98.6 million in 2024, then soared by 83.78% to $181.2 million in 2025, then decreased by 4.34% to $173.3 million in 2026.
  • Business Quant data shows Assets for IKT at $173.3 million in Q1 2026, $181.2 million in Q4 2025, and $79.6 million in Q3 2025.